Feasibility of cabazitaxel in octogenarian prostate cancer patients

CONCLUSIONS: Octogenarian patients can be treated with cabazitaxel with reduced doses or alternative schedules that are associated with less toxicity and fewer treatment interruptions. Comprehensive geriatric assessment could facilitate more appropriate patient selection.PMID:37448615 | PMC:PMC10337820 | DOI:10.1097/CU9.0000000000000081

Source: Cancer Control - July 14, 2023 Category: Cancer & Oncology Authors: Paolo Tralongo Sebastiano Bordonaro Giuseppe Di Lorenzo Ugo De Giorgi Nicol ò Borsellino Gaetano Facchini Sabrina Rossetti Giuseppe Fornarini Vito Longo Antonino Carmelo Tralongo Francesca Caspani Massimiliano Spada Nicola Calvani Paolo Carlini Source Type: research